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Summary
Maybe most characteristic of the TargetFish1 project, which kicked off some five years ago with 30 
partners from 10 EU member states, two associated countries (Norway, Israel) and one international 
cooperation partner country (Chile), has been the close cooperation between research groups and 
enterprises; more or less equally represented in this large consortium. In this respect, TargetFish 
has been revolutionary validating by this close cooperation fundamental knowledge for the devel-
opment of next generation vaccines and different routes of vaccine administration. TargetFish had 
the ambition to demonstrate market applicability of improved vaccines or new prototype vaccines 
that would come forward from the project. Via frequent joint meetings of its partners, be it research 
group or enterprise, TargetFish aimed to drive vaccine development in an industrial applicable way. 
This could facilitate adoption of new intellectual property and stimulate the presentation of new 
fish vaccines on the market. The industry forum has been a platform for a continuing validation of 
the applied potential of the research outcomes. Workshops were organised at the different EAFP 
meetings to communicate the validation process to those not directly involved with the project but 
interested in the fish vaccine market. After a kick-off meeting during the EAFP in Tampere, Finland 
fours years ago and a second meeting at the EAFP in Las Palmas, Spain, two years ago, at the present 
EAFP in Belfast, Northern Ireland a final meeting was organised. This report is a summary of the 
‘Industrial Forum workshop’ held at the EAFP in Belfast 2017 and provides a short overview of the 
highlights presented to, and discussed with, those present and interested in DNA vaccine develop-
ment, policies and laws, production and delivery routes.
1TargetFish is a large collaborative project funded by the European Commission under the 7th Framework 
Programme for Research and Technological Development (FP7) of the European Union (Grant Agreement 
311993) aiming to ‘improve fish vaccination strategies to help prevent important diseases in the European 
aquaculture industry’.
* Corresponding author’s email: geert.wiegertjes@wur.nl, targetfish.cbi@wur.nl
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DNA vaccines
Traditionally, many fish vaccines have been 
based on inactivated bacteria or viruses, and 
although several of these have been extremely 
(cost) effective, not all disesases caused by fish 
pathogens can be prevented with these rela-
tively simple forms of vaccines. More recently, 
a new approach to vaccination has been devel-
oped, involving the direct introduction into 
appropriate tissues of a DNA plasmid encoding 
the protective antigen of the pathogen causing 
the disease to be prevented. Upon administra-
tion into the host (usually muscle) tissue, some 
cells will take up the DNA vaccine and express 
the pathogen protein. The host will recognise 
the protein as non-self and mount a protective 
immune response through stimulation of both 
innate and adaptive immune mechanisms.
Regulatory requirements for the 
authorisation of DNA vaccines for fish 
in the EU
DNA vaccines are classified as immunologi-
cal veterinary medicinal products under EU 
legislation and are thus subject to the relevant 
directive (EC Directive 2001/82/EC). As vac-
cines developed by recombinant technology 
they are subject to authorisation through the 
European Medicines Agency (Regulation (EC) 
726/2004). Further, the manufacture of DNA 
vaccines should comply with the rules on good 
manufacturing practice (GMP) for veterinary 
medicinal products (EC Directive 91/412). 
Additionally, there are some specific regula-
tory guidelines that are applicable to DNA 
vaccines, for example the guideline on ‘DNA 
vaccines non-amplifiable in eukaryotic cells 
for veterinary use’ (EMA/CVMP/IWP/07/98). 
There are also some specific regulatory issues 
for DNA vaccines in addition to those required 
for more conventional aquaculture vaccines, 
which address potential safety concerns. Impor-
tant points to consider include: 1) the definition 
of a DNA vaccine in the context of the legal 
framework and whether such products could 
be classified as genetically modified organisms 
(GMOs) and subject to the relevant legislation 
(EC Directive on the deliberate release into the 
environment of genetically modified organisms 
2001/18/EC), 2) safety for the consumer, envi-
ronment and target species, 3) proof of efficacy 
in laboratory and - unless justified - supported 
with field studies, 4) a benefit-risk assessment. 
Highly relevant to some sectors of aquaculture 
are the regulatory requirements in the guide-
line for immunological veterinary medicinal 
products intended for minor use or minor 
species (MUMS)/limited market (EMA/CVMP/
IWP/123243/2006-Rev.3). The data requirements 
for authorisation of a DNA vaccine that is eligi-
ble for classification as a MUMS application are 
reduced. Thus, this applies when the vaccine is 
intended for use in a minor species (most fish 
species) only, or when a disease is relevant in 
a major species but for minor use, or if the re-
spective vaccine has a limited market. This was 
the case for a DNA vaccine for Atlantic salmon 
recently authorised for use in the EU (Clynav, 
against Salmon Pancreatic Disease, SPD). Key 
regulatory points on DNA vaccines include:
DNA vaccines are new innovative veterinary 
products for regulators. DNA vaccines are not 
classified as GMO. The DNA plasmid vaccine 
by itself cannot be considered a GMO, since 
it is a construct and not a replicating living 
organism. However, this may not apply to all 
DNA vaccines should the vector be designed to 
integrate into the genome of the target species.
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Target species safety studies should address 
the requirements under legislation. The safety 
studies should be carried out in the target 
species and the dose to be used for the safety 
study should be the dose recommended for use. 
The product should be produced according to 
the manufacturing process.
Although DNA vaccines are not classified as live 
vaccines it is considered prudent to approach 
some of the safety studies for such products. 
The safety study could be conducted as a 10-fold 
overdose and studies should include dissemi-
nation of the DNA in the target animal with 
consideration for the potential integration into 
relevant organs and tissues including gonadal 
tissue.
The safety for the user and consumer should 
demonstrate a negligible risk for humans 
exposed to the vaccine.
An environmental risk assessment (ERA) should 
be extensive depending on the potential en-
vironments the product may be used in and 
include quantitative assessment with conse-
quence analysis.
Potential integration into the genome of the 
vaccinated animal is a critical safety issue and 
should be thoroughly investigated through the 
relevant laboratory safety studies and environ-
mental risk assessment.
Why are DNA vaccines not GMOs?
A DNA plasmid vaccine by itself cannot be con-
sidered a GMO, since a plasmid is a construct 
and not capable, on its own, to replicate or 
transfer genetic material into the genome of the 
fish. Therefore, a plasmid cannot be regarded 
as a biologically viable entity. Yet, even if not a 
GMO, there is the question as to whether fish 
vaccinated with the plasmid become GMOs, 
where the latter are defined as organisms in 
which the genetic material has been altered in 
a way that does not occur naturally by mating 
and/or natural recombination. Although the 
position for future DNA vaccines still remains 
unclear, the answer appears to be no-they-are-
not from the recent decision of a GMO authority 
for fish vaccinated with the first DNA vaccine 
authorised in the EU. 
The pros and contras of DNA 
vaccination against SPD for Atlantic 
salmon culture in Norway
The Norwegian Medicines Agency (NOMA) 
has voiced an opposition or divergent position 
against the Clynav plasmid vaccine to be used 
to protect Atlantic salmon against PD caused by 
subtype 3 of SPDV. NOMA’s opposition is based 
on lack of real duration of immunity (DOI) 
studies, where current DOI is only 2 months. 
It is NOMA’s standing this (short duration of 
protection) cannot outweigh the risks related 
to animal safety, potential lack of protection 
beyond 2 months, potential interaction with 
other vaccines currently used in Norway and 
potential reduction in fillet quality as a conse-
quence of intramuscular injection of the vaccine. 
The volume injected is also considered high 
given it will go into the epaxial muscle or the 
back loin of the fish. The latter concern comes 
from the observation that local and general 
reactions to the injected plasmid solution were 
seen under laboratory testing. 
Yet another concern that was raised initially was 
the GMO issue, i.e. that vaccinated fish would 
be considered GMOs and thus labelling of the 
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final product would be required. Based on an 
EFSA assessment where it was concluded that 
“the actual integration rate is likely to be orders 
of magnitude lower than the upper estimated 
integration rate calculated in the context of 
the worst-case scenarios” (EFSA Journal, doi: 
10.2903/j.efsa.2017.4689), this should be un-
derstood in such a way that the likelihood of 
integration is considered negligible. On this 
basis the conclusion from the Norwegian side 
is that Atlantic salmon vaccinated with Clynav 
will not be considered GMO. This is a decision 
made on a case-by-case basis and not a general 
standing of the Norwegian authorities. 
Evaluating the level of genomic 
integration after DNA vaccination
As discussed above, DNA vaccines are generally 
not considered GMOs, unless the plasmid was 
specifically engineered to integrate and main-
tain genomic integration. If not the case, integra-
tion should be considered a random occurrence 
and would not present any additional risk as 
compared to e.g. the rate of natural spontane-
ous mutation. Yet, integration studies may be 
required for future applications on DNA vac-
cination. Stimulated by the DNA vaccine guid-
ance, TargetFish ‘travelled down this road’ by 
experimentally addressing genomic integration 
of plasmid DNA after intramuscular injection. 
In TargetFish we designed an experimental 
DNA vaccine based on the structural protein 
of subtype 1 of SPDV to study genomic integra-
tion in muscle samples from DNA-vaccinated 
Atlantic salmon collected for several days 
post-vaccination at the site of i.m. injection. 
To evaluate the limit of detection, genomic 
DNA from unvaccinated salmon muscle tissue 
was mixed with increasing amounts of DNA 
from a recombinant salmonid cell line with 
the DNA vaccine construct integrated into its 
genome. These data mimicked different levels of 
genomic integration and were used to establish 
a calibration curve. Finally, 1) the purification of 
high molecular weight genomic DNA exclud-
ing free plasmid followed by 2) an enrichment 
step for fragments containing the DNA vaccine 
sequence and 3) deep sequencing, will help 
identify and count sequences with both salmon 
genome and plasmid DNA in order to estimate 
the integration rate using the calibration curve. 
This approach to study integration after DNA 
vaccination will be useful also long after Tar-
getFish is finished.
Applied aspects of DNA vaccination
Some of the most efficient DNA vaccines de-
scribed to date are those against fish rhabdovi-
ruses. By mediating expression of the viral gly-
coprotein (G) in vaccinated fish, these vaccines 
induce rapid and long lasting protection against 
the respective viruses. A DNA vaccine known 
as Apex-IHN has been used commercially for 
protection of sea-reared Atlantic salmon against 
infectious haematopoietic necrosis (IHN) in 
British Columbia, Canada, since 2005. To date, 
no outbreaks of IHN have been reported among 
the vaccinated fish. A related disease in Euro-
pean rainbow trout is called viral haemorrhagic 
septicaemia (VHS), or “Egtved disease” named 
after the village in Denmark where it was first 
recognised. Although historically, VHS may 
have been associated mostly with aquaculture of 
freshwater salmonids in Western Europe to date 
the virus is known to affect over 80 freshwater 
and marine fish species worldwide. It may be 
clear that vaccination against VHS can indeed be 
highly relevant, both in Europe or worldwide, 
in freshwater or marine environments. 
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There is ample evidence of the effectiveness of 
DNA vaccination against VHS, at least when 
based on the i.m. injection of G-protein encoding 
plasmids. The advantages of DNA vaccines for 
VHS are multiple and include 1) high safety – no 
risk of disease, 2) rapid and long-lasting protec-
tion, 3) no additional adjuvant needed, 4) high 
stability and 5) simple to produce. Given the dis-
cussion above on legislation, commercialisation 
of DNA vaccination against VHS may become a 
realistic option in the near future, although there 
will be local restrictions related to the disease 
status. In Denmark and some other countries in 
Europe the virus has been eliminated from the 
freshwater by, e.g. replacing earthen ponds for 
intensive recirculation systems and by stamping 
out procedures. However, VHSV is still present 
in the marine environment, also in Denmark. 
In Europe, VHS is a notifiable disease and falls 
under Council Directive 2006/88/EC: Member 
States shall ensure that vaccination against the 
non-exotic diseases listed in Part II of Annex 
IV is prohibited in any parts of their territory 
declared free of the diseases in question, or 
covered by a surveillance programme. Although 
vaccination against notifiable diseases is gener-
ally prohibited, member states may allow vac-
cination in parts of their territory not declared 
free from the diseases in question, or where 
vaccination is part of an eradication programme.
New routes of delivery for DNA 
vaccines
There are several (experimental) DNA vaccines 
that when injected i.m. protect very well against 
a subsequent lethal challenge and provide 
values for relative percentage survival (RPS) 
>90% for months after a single administration of 
plasmid. Often, a local inflammatory response 
in the muscle tissue is observed immediately 
after injection and may be responsible for trig-
gering a first period of innate immunity, fol-
lowed by a highly specific response after a few 
weeks (depending of course on the temperature) 
correlating with occurrence of specific antibod-
ies induced locally (IgM, IgT) and/or systemi-
cally (IgM). 
Of specific interest are attempts to protect fish 
against disease with an oral DNA vaccine, with 
successes reported for infectious pancreatic 
necrosis virus (IPNV) in rainbow trout. High 
protection with RPS values of 85% were ob-
tained, albeit based on much higher dosages 
of plasmid than needed for i.m. vaccination. In 
addition, oral DNA vaccination of several fish 
species against bacteria has been reported with 
RPS values of 60-70% after challenge, suggesting 
DNA vaccination by oral route could become a 
reality in the near future. However, time course 
studies and specificity of the protective mecha-
nisms still remain to be determined for several 
of these vaccines. On the other hand, DNA 
vaccines based on the G-protein of rhabdovi-
ruses, so extremely efficacious when injected 
i.m., have so far yielded limited success when 
applied orally. Here, despite active transcription 
of the G protein and induction of local immune 
responses, serum antibodies and protection 
appear mostly absent when the DNA vaccine is 
provided orally. Possibly, the optimal route for 
induction of protection by DNA vaccines could 
be linked to the nature of the actual disease, 
including parameters such as the natural site of 
pathogen entry and systemic versus local propa-
gation of the infection. Further studies are re-
quired to clarify these aspects and to determine 
how several parameters such as encapsulation 
method, adjuvant effect, vaccine concentration 
and delivery regime might require individual 
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optimisation for oral (mucosal?) DNA vaccines. 
This puts forward a plethora of questions to 
address in the near future, including aspects 
of oral tolerance.
What’s next?
Clearly, DNA vaccines can be highly efficacious 
and safe, do not require adjuvants, have high 
stability and are relatively simple to produce. 
Some DNA vaccines can induce rapid and long-
lasting protection when injected i.m., while 
others are able to trigger a protective response 
(also) when administered orally. The regula-
tory requirements and extent of data needed to 
support an application for registration of a DNA 
vaccine are strongly reduced when the applica-
tion qualifies for use in minor species, or disease 
in major species which are of minor importance, 
or have a limited market (MUMS). This might 
facilitate commercialisation of DNA vaccines for 
use in aquaculture. Although in the light of a 
growing importance of aquaculture and animal 
welfare connected with disease outbreaks and 
their eradication it cannot be excluded that the 
MUMS issue for farmed fish might be revised 
in the future, with a DNA vaccine for Atlantic 
salmon authorised for use in the EU in 2017, the 
future of DNA vaccination for disease prophy-
laxis in farmed fish is brighter than ever before. 
Yet, there are several key regulatory issues that 
remain to be further explored such as genomic 
integration and risk to the environment which, 
along with practical challenges like plasmid 
vector design and determination of optimal 
route of (oral?) administration, will remain key 
issues for future research.
